Araris Biotech AG Secures Strategic Investment from Samsung Ventures

Araris Biotech AG, a frontrunner in the development of proprietary antibody-drug conjugate (ADC)-linker technology, has recently secured an investment from Samsung Venture Investment Corporation, Samsung's investment arm committed to fostering the growth of new technologies. This strategic investment is part of an independent deal ahead of Araris' ongoing series A funding round. The Role of Samsung Life Science Fund The investment was made through the Samsung Life Science Fund, a joint venture between Samsung Biologics and Samsung C&T, and managed by Samsung Ventures. This move aligns with Samsung's commitment to broaden its business interests in the biopharmaceutical domain. ADC-Linker Technology: A Game Changer in Drug Therapies Araris Biotech AG is leading the way with its proprietary ADC-linker technology. This innovative platform enables the attachment of payload to readily available antibodies without the need for reengineering or reducing antibodies. This results in the production of highly stable, potent ADC therapies in a time and cost-efficient manner. The technology also potentially addresses challenges linked with ADCs, such as solubility and unstable linkage issues. This recent investment signifies Samsung's commitment to further expand its pipeline. Collaboration with Samsung As a strategic investor, Samsung will work closely with Araris on the evaluation, manufacturing, and development of assets using Araris' proprietary ADC technology. The collaboration involves Samsung affiliates that are in the discovery, development, and manufacturing of novel biologics. John Rim, CEO of Samsung Biologics, expresses his optimism about the collaboration. "Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs." The Perspective of Araris Biotech Philipp Spycher, Ph.D., CEO and co-founder of Araris Biotech, expressed his gratitude for the support from Samsung. He sees this as an acknowledgment of the potential of their linker-payload toolbox and conjugation technology in the rapidly growing ADC field. "We look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic." About Araris Biotech AG Araris Biotech AG is pioneering the development of its novel ADC-linker technology to enable the efficient and precise production of ADCs. Its linker platform allows the attachment of any drug payload to 'off the shelf' antibodies, without the need for prior antibody engineering. The resulting ADCs have demonstrated very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. About Samsung Ventures Samsung Venture Investment Corporation was established to promote promising small and medium-sized companies engaging in the development of new technologies. They are known for their active investment in future-oriented businesses based on new and innovative technologies expected to serve as new growth engines. Accelerate Strategic R&D decision making with Synapse Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals, can help accelerate strategic R&D decision making. Conclusion This strategic investment is a significant milestone for Araris Biotech AG as it further validates the potential of their ADC-linker technology. The collaboration with Samsung Ventures is expected to accelerate the development and advancement of Araris' ADC candidates.

References:

Synapse: Global Drug Intelligence Database